For 2026, 2.6 million seniors saw their MA prescription drug plans discontinued, double last year’s total. This erosion is not an accident of the market — it is the direct, predictable consequence of flawed policy, and it’s putting the stability of a vital program in jeopardy.
These policy changes stem from an inaccurate Washington narrative that claims MA has failed to reduce Medicare spending.
This is simply not true. MA is a vital program for the majority of Medicare beneficiaries, and policymakers must focus on stabilizing the program over undermining it. ARTICLE